PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™

Informations

• Publié par: pds-biotechnology-corporation
• Nombre de lectures: 17
• Langue: English

Extrait

PDS Biotechnology Corporation Signs

Worldwide Licensing Agreement with Merck

KGaA for Versamune™

PR Newswire

LAWRENCEBURG, Indiana, July 9, 2012

LAWRENCEBURG, Indiana

,

July 9, 2012

/PRNewswire/ -- PDS Biotechnology

Corporation announced today that they have entered into an exclusive

worldwide licensing agreement with Merck KGaA, Darmstadt,

Germany

, for use

of PDS Biotechnology's novel Versamune™ nanotechnology platform in two of

Merck's investigational antigen-specific cancer immunotherapies currently in

pre-clinical development. Merck obtains the rights to utilize the technology with

two investigational antigen-specific cancer immunotherapies which are in pre-

clinical development.

Under the terms of the licensing agreement, PDS Biotechnology Corporation

will receive an undisclosed upfront payment in cash, as well as development

milestone payments, and commercial and sales milestone payments. PDS

Biotechnology Corporation will also receive royalties on sales of the products

incorporating the technology.

Dr. Frank Bedu-Addo, Chief Executive of PDS Biotechnology Corporation said,

"We are very pleased that Merck which is experienced in the clinical

development of cancer immunotherapies would like to utilize the Versamune™

technology. For PDS Biotechnology Corporation, this deal is important since the

company's business strategy is focused on a few strategic out-licensing or

partnering deals at a preclinical or early clinical stage. This is the stage where

companies will be seeking to enhance their pipelines by taking advantage of a

new technology that has broad potential applications in clinical research into

the treatment and prevention of cancer and infectious diseases."

About PDS Biotechnology Corporation and Versamune™

PDS Biotechnology Corporation is a privately held biotechnology company

founded to exploit the newly discovered properties of specific synthetic

positively charged (cationic) lipids to commercialize a new generation of

immunotherapies and vaccines. The proprietary Versamune™ platform

nanotechnology, when combined with specific cancer-associated molecules,

has been demonstrated to lead to increased tumor regression rates compared

to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology

Immunotherapy, 2008, 57: (4) 517-530). The Versamune™ nanotechnology

presents a giant step forward in the development of the next generation of

immunotherapies. PDS Biotechnology Corporation's lead products are being

developed to treat prevalent cancers such as cervical cancer, head and neck

cancer and melanoma. The technology is also being applied to the

development of vaccines which are designed to protect against pandemic

diseases. Visit www.pdsbiotech.com for more information on Versamune™ and

products in development.